Abstract

The talk will describe our strategy for combining functional genomic and chemogenomic screening approaches to find new targets for drug discovery. GSK’s Chemogenomic screening platform has been re-designed and expanded to facilitate its application, alongside genetic screening, in disease relevant primary cellular systems such as iPSC derived macrophages and T cells. The talk will outline our current chemogenomic capability and our strategy for alignment of this capability with CRIPSR screens to identify tractable, genetically validated targets.